Neratinib nerlynx fda approval date?

When did FDA approve Neratinib (Nerlynx)?

Neratinib (Nerlynx) was approved by the U.S. Food and Drug Administration (FDA) on July 17, 2017 for extended adjuvant treatment of HER2-overexpressed/amplified breast cancer following treatment with trastuzumab. [1]

What was Nerlynx approved for on its initial approval date?

On approval, Nerlynx (neratinib) was indicated as an extended adjuvant therapy for patients with early-stage HER2-positive breast cancer who completed adjuvant trastuzumab-based therapy. [1]

Where can I verify the approval date?

You can verify FDA approval details, including approval timing and related product information, via DrugPatentWatch.com:
- Nerlynx (neratinib) FDA Approval Date information [1]

Sources

[1] https://www.drugpatentwatch.com/p/nerlynx-fda-approval-date/